Back to Search
Start Over
Lenalidomide for the treatment of B-cell lymphoma.
- Source :
-
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2016 Sep; Vol. 25 (9), pp. 1103-16. Date of Electronic Publication: 2016 Jul 22. - Publication Year :
- 2016
-
Abstract
- Introduction: Although the combination of an anti-CD20 monoclonal antibody and chemotherapy has widely improved survival of patients with B-cell lymphoma, the disease still relapses. A better understanding of the biology of lymphomas has highlighted the role of the cell of origin in response to treatment and outcome. Lenalidomide represents an attractive therapeutic option due to its original mechanism of action.<br />Areas Covered: In this review, the authors describe the pharmacological properties of lenalidomide, and the rational for its use in B-cell lymphomas; focusing on diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). They discuss the mechanism of action of the drug and its current and future clinical development. They also review the current data in relapsed/refractory situations as well as in first-line treatment.<br />Expert Opinion: Lenalidomide is an oral non-chemotherapy immunomodulatory agent with an acceptable toxicity profile and manageable side-effects. Efficacy has widely been demonstrated, especially in MCL, FL and non-Germinal Center DLBCL patients. Further studies are now warranted to better define the strategy for the use of lenalidomide in B-NHL patients, and clarify which subgroup of patients will really benefit of lenalidomide as part of first-line treatment or in a relapsed/refractory setting.
- Subjects :
- Antineoplastic Combined Chemotherapy Protocols
Clinical Trials as Topic
Disease-Free Survival
Humans
Immunologic Factors adverse effects
Immunologic Factors pharmacokinetics
Immunologic Factors pharmacology
Lenalidomide
Lymphoma, B-Cell immunology
Lymphoma, B-Cell mortality
Lymphoma, Follicular drug therapy
Lymphoma, Follicular immunology
Lymphoma, Follicular mortality
Lymphoma, Large B-Cell, Diffuse drug therapy
Lymphoma, Large B-Cell, Diffuse immunology
Lymphoma, Large B-Cell, Diffuse mortality
Lymphoma, Mantle-Cell drug therapy
Lymphoma, Mantle-Cell immunology
Lymphoma, Mantle-Cell mortality
Thalidomide adverse effects
Thalidomide pharmacokinetics
Thalidomide pharmacology
Thalidomide therapeutic use
Immunologic Factors therapeutic use
Lymphoma, B-Cell drug therapy
Thalidomide analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7658
- Volume :
- 25
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Expert opinion on investigational drugs
- Publication Type :
- Academic Journal
- Accession number :
- 27414850
- Full Text :
- https://doi.org/10.1080/13543784.2016.1208170